{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:23:52Z","timestamp":1791559432766,"version":"4.3.4"},"reference-count":31,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Brazilian National Council for Scientific and Technological Development","doi-asserted-by":"publisher","award":["305659\/2023-5"],"award-info":[{"award-number":["305659\/2023-5"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"INCT-Bio2\u2013Biodescoberta Translacional e Biomodelos","doi-asserted-by":"publisher","award":["408566\/2024-8"],"award-info":[{"award-number":["408566\/2024-8"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"PPSUS Innovation\u2014Class 2: Social and Institutional Innovations","doi-asserted-by":"publisher","award":["444227\/2025-3"],"award-info":[{"award-number":["444227\/2025-3"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Oncol.","Current Oncology"],"abstract":"<jats:p>The use of targeted therapies has improved outcomes in patients with resected epidermal growth factor receptor-mutated non-small cell lung cancer, but uncommon and persistent dermatologic toxicities remain poorly characterized. We report a 71-year-old woman with resected lung adenocarcinoma harboring an epidermal growth factor receptor exon 21 L858R mutation. Following right upper lobectomy and systematic mediastinal lymph node dissection, pathological staging was pT2aN1M0 (stage IIB). She received four cycles of adjuvant cisplatin plus pemetrexed followed by planned three-year adjuvant Osimertinib. During Osimertinib treatment, she developed a persistent violaceous rash accompanied by progressive cutaneous hyperpigmentation. Osimertinib was temporarily interrupted, and dermatologic evaluation was performed, resulting in partial clinical improvement. Hyperpigmentation, however, persisted during follow-up. Other adverse events included grade 1 diarrhea, transient arthralgia, anorexia, and weight loss. Osimertinib was subsequently resumed and maintained. Nearly two years after surgery, the patient remains free of disease recurrence, with stable pigmentary skin changes. This case highlights an uncommon and prolonged dermatologic manifestation associated with Osimertinib and emphasizes the importance of recognizing atypical cutaneous toxicity to facilitate appropriate management and to facilitate appropriate dermatologic evaluation and individualized management of treatment-related toxicity.<\/jats:p>","DOI":"10.3390\/curroncol33090536","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:10:33Z","timestamp":1788430233000},"page":"536","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-Term Cutaneous Hyperpigmentation During Adjuvant Osimertinib Therapy in a Resected Stage IIB EGFR L858R-Mutated Lung Adenocarcinoma in an Older Adult: A Rare Case Report with Two-Year Follow-Up and Literature Review"],"prefix":"10.3390","volume":"33","author":[{"given":"Marclesson Santos","family":"Alves","sequence":"first","affiliation":[{"name":"Pronutrir Oncology Clinic, Fortaleza 60810-180, CE, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana Pal\u00e1cio de Queiroz","family":"Ventura Barros","sequence":"additional","affiliation":[{"name":"Pronutrir Oncology Clinic, Fortaleza 60810-180, CE, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle Calheiros Campelo","family":"Maia","sequence":"additional","affiliation":[{"name":"Pronutrir Oncology Clinic, Fortaleza 60810-180, CE, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0127-3698","authenticated-orcid":false,"given":"Igor Santos","family":"Costa","sequence":"additional","affiliation":[{"name":"Argos Patologia, Fortaleza 60175-047, CE, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ormando Rodrigues","family":"Campos Junior","sequence":"additional","affiliation":[{"name":"Pronutrir Oncology Clinic, Fortaleza 60810-180, CE, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2431-4779","authenticated-orcid":false,"given":"Howard Lopes","family":"Ribeiro Junior","sequence":"additional","affiliation":[{"name":"Post-Graduate Program in Pathology, Post-Graduate Program in Translational Medicine, Center for Research and Drug Development (NPDM), Federal University of Cear\u00e1, Fortaleza 60430-275, CE, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"ref_1","first-page":"e70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41392-025-02243-6","article-title":"Advances in molecular pathology and therapy of non-small cell lung cancer","volume":"10","author":"Huang","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40364-024-00566-0","article-title":"Oncogenic alterations in advanced NSCLC: A molecular super-highway","volume":"12","author":"Friedlaender","year":"2024","journal-title":"Biomark. Res."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Rosas, D., Desai, J., and Raez, L. (2026). Therapeutic Advances in Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations: From Molecular Biology to Targeted Therapy. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27093714"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1007\/s00432-020-03296-6","article-title":"Non-small cell lung cancer patients with ex19del or exon 21 L858R mutation: Distinct mechanisms, different efficacies to treatments","volume":"146","author":"Li","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-20-0103","article-title":"Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I","volume":"19","author":"Lim","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Bertoli, E., De Carlo, E., Del Conte, A., Stanzione, B., Revelant, A., Fassetta, K., Spina, M., and Bearz, A. (2022). Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23136936"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"103435","DOI":"10.1016\/j.eclinm.2025.103435","article-title":"Osimertinib plus consolidative radiotherapy for advanced EGFR mutant non-small cell lung cancer: A multicentre, single-arm, phase 2 trial","volume":"87","author":"Sampath","year":"2025","journal-title":"EClinicalMedicine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1007\/s10147-025-02868-1","article-title":"Epidermal growth factor receptor inhibitor-related skin toxicities: A review of management and possible preventive and therapeutic approaches for Asian patients by the Japanese Pharmacist-led Oncodermatology Study Team","volume":"30","author":"Iimura","year":"2025","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"bcr2013201554","DOI":"10.1136\/bcr-2013-201554","article-title":"The CARE guidelines: Consensus-based clinical case reporting guideline development","volume":"2","author":"Gagnier","year":"2013","journal-title":"BMJ Case Rep."},{"key":"ref_14","first-page":"1079","article-title":"MASCC Skin Toxicity Study Group. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities","volume":"19","author":"Lacouture","year":"2011","journal-title":"Support. Care Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/1759-7714.13378","article-title":"Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced\/recurrent non-small cell lung carcinoma","volume":"11","author":"Kishikawa","year":"2020","journal-title":"Thorac. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13045-022-01391-4","article-title":"Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with Osimertinib resistance","volume":"15","author":"Fu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2016.70.3223","article-title":"Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component","volume":"35","author":"Yang","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2478\/prilozi-2024-0025","article-title":"Osimertinib-Induced Toxic Epidermal Necrolysis\u2014A Case Report","volume":"45","author":"Crvenkova","year":"2024","journal-title":"PRILOZI"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/1759-7714.14383","article-title":"Rare ashy dermatosis-like hyperpigmentation associated with Osimertinib","volume":"13","author":"Funai","year":"2022","journal-title":"Thorac. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Ling, M., Wang, M., Chen, Y., and Zhang, L. (2025). Rare skin adverse reactions induced by Osimertinib: A case report and literature review. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1523541"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Sato, I., Mizuno, H., Kataoka, N., Kunimatsu, Y., Tachibana, Y., Sugimoto, T., Tani, N., Ogura, Y., Hirose, K., and Takeda, T. (2020). Osimertinib-Associated Toxic Epidermal Necrolysis in a Lung Cancer Patient Harboring an EGFR Mutation-A Case Report and a Review of the Literature. Medicina, 56.","DOI":"10.3390\/medicina56080403"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1634\/theoncologist.2017-0582","article-title":"Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer","volume":"23","author":"Chu","year":"2018","journal-title":"Oncologist"},{"key":"ref_24","first-page":"289","article-title":"Immunological features of EGFR-mutant non-small cell lung cancer and clinical practice: A narrative review","volume":"4","author":"Dong","year":"2024","journal-title":"J. Natl. Cancer Cent."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Rachiglio, A.M., Fenizia, F., Piccirillo, M.C., Galetta, D., Crin\u00f2, L., Vincenzi, B., Barletta, E., Pinto, C., Ferra\u00f9, F., and Lambiase, M. (2019). The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients. Cancers, 11.","DOI":"10.3390\/cancers11030341"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"108463","DOI":"10.1016\/j.lungcan.2025.108463","article-title":"EGFR mutation status affects intra-tumoural heterogeneity of PD-L1 expression but not agreement between assays in resectable non-small cell lung cancer","volume":"202","author":"Saw","year":"2025","journal-title":"Lung Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jdcr.2019.11.008","article-title":"Osimertinib-associated ashy dermatosis-like hyperpigmentation","volume":"6","author":"Lertpichitkul","year":"2020","journal-title":"JAAD Case Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"bcr2017224144","DOI":"10.1136\/bcr-2017-224144","article-title":"EGFR inhibitor-induced cut-like skin lesions of the fingers","volume":"2018","author":"Iskandar","year":"2018","journal-title":"BMJ Case Rep."},{"key":"ref_29","first-page":"101026","article-title":"Osimertinib retreatment for patients with advanced EGFR-mutated non-small cell lung cancer","volume":"45","author":"Levine","year":"2025","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Gomatou, G., Syrigos, N., and Kotteas, E. (2023). Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options. Cancers, 15.","DOI":"10.3390\/cancers15030841"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1038\/s41591-025-03577-y","article-title":"Molecular residual disease analysis of adjuvant Osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer","volume":"31","author":"Herbst","year":"2025","journal-title":"Nat. Med."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/9\/536\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:47:09Z","timestamp":1788432429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/9\/536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["curroncol33090536"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33090536","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]}}}